• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Fc 结构域和渗出在 L2 抗体介导的人乳头瘤病毒保护中的作用。

Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

机构信息

Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.

Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.

出版信息

J Virol. 2018 Jul 17;92(15). doi: 10.1128/JVI.00572-18. Print 2018 Aug 1.

DOI:10.1128/JVI.00572-18
PMID:29743371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6052307/
Abstract

To address how L2-specific antibodies prevent human papillomavirus (HPV) infection of the genital tract, we generated neutralizing monoclonal antibodies (MAbs) WW1, a rat IgG2a that binds L2 residues 17 to 36 (like mouse MAb RG1), and JWW3, a mouse IgG2b derivative of Mab24 specific for L2 residues 58 to 64. By Western blotting, WW1 recognized L2 of 29/34 HPV genotypes tested, compared to only 13/34 for RG1 and 25/34 for JWW3. WW1 IgG and F(ab') bound HPV16 pseudovirions similarly; however, whole IgG provided better protection against HPV vaginal challenge. Passive transfer of WW1 IgG was similarly protective in wild-type and neonatal Fc receptor (FcRn)-deficient mice, suggesting that protection by WW1 IgG is not mediated by FcRn-dependent transcytosis. Rather, local epithelial disruption, required for genital infection and induced by either brushing or nonoxynol-9 treatment, released serum IgG in the genital tract, suggesting Fc-independent exudation. Depletion of neutrophils and macrophages reduced protection of mice upon passive transfer of whole WW1 or JWW3 IgGs. Similarly, IgG-mediated protection by L2 MAbs WW1, JWW3, and RG1 was reduced in Fc receptor knockout compared to wild-type mice. However, levels of neutralization by WW1 IgG were similar in TRIM21 knockout and wild-type cells, indicating that Fc does not contribute to antibody-dependent intracellular neutralization (ADIN). In conclusion, the Fc domain of L2-specific IgGs is not active for ADIN, but it opsonizes bound extracellular pseudovirions for phagocytes in protecting mice from intravaginal HPV challenge. Systemically administered neutralizing IgG can access the site of infection in an abrasion via exudation without the need for FcRn-mediated transcytosis. At least 15 alpha HPV types are causative agents for 5% of all cancers worldwide, and beta types have been implicated in nonmelanoma skin cancer, whereas others produce benign papillomas, such as genital warts, associated with considerable morbidity and health systems costs. Vaccines targeting the minor capsid protein L2 have the potential to provide broad-spectrum immunity against medically relevant HPVs of divergent genera via the induction of broadly cross-neutralizing serum IgG. Here we examine the mechanisms by which L2-specific serum IgG reaches the viral inoculum in the genital tract to effect protection. Abrasion of the vaginal epithelium allows the virus to access and infect basal keratinocytes, and our findings suggest that this also permits the local exudation of neutralizing IgG and vaccine-induced sterilizing immunity. We also demonstrate the importance of Fc-mediated phagocytosis of L2 antibody-virion complexes for humoral immunity, a protective mechanism that is not detected by current neutralization assays.

摘要

为了解 L2 特异性抗体如何预防人类乳头瘤病毒(HPV)感染生殖道,我们生成了中和单克隆抗体(MAbs)WW1,这是一种与人乳头瘤病毒 29 型结合的大鼠 IgG2a,结合 L2 残基 17 至 36(与小鼠 MAb RG1 类似),以及针对 L2 残基 58 至 64 的小鼠 IgG2b 衍生物 JWW3。通过 Western blot,WW1 识别 29/34 种测试的 HPV 基因型的 L2,而 RG1 仅识别 13/34,JWW3 仅识别 25/34。WW1 IgG 和 F(ab') 类似地结合 HPV16 假病毒;然而,完整的 IgG 提供了更好的 HPV 阴道挑战保护。WW1 IgG 的被动转移在野生型和新生儿 Fc 受体(FcRn)缺陷型小鼠中同样具有保护作用,表明 WW1 IgG 的保护作用不是由 FcRn 依赖性转胞吞介导的。相反,局部上皮破坏是生殖道感染所必需的,无论是通过刷洗还是非诺酮-9 处理诱导的,都会将血清 IgG 释放到生殖道中,这表明 Fc 不依赖外渗。耗尽中性粒细胞和巨噬细胞会降低 WW1 或 JWW3 完整 IgG 被动转移时小鼠的保护作用。同样,与野生型小鼠相比,L2 MAb WW1、JWW3 和 RG1 的 IgG 介导的保护作用在 Fc 受体敲除小鼠中降低。然而,WW1 IgG 的中和水平在 TRIM21 敲除和野生型细胞中相似,表明 Fc 不参与抗体依赖性细胞内中和(ADIN)。总之,L2 特异性 IgG 的 Fc 结构域对于 ADIN 没有活性,但它可以调理结合的细胞外假病毒,以便吞噬细胞吞噬,从而保护小鼠免受阴道内 HPV 挑战。系统给予的中和 IgG 可以通过渗出作用进入通过擦伤到达感染部位,而无需 FcRn 介导的转胞吞作用。至少有 15 种 alpha HPV 类型是全球 5%所有癌症的致病因素,而 beta 类型与非黑色素瘤皮肤癌有关,而其他类型则产生良性乳头瘤,如生殖器疣,这些疾病会导致相当大的发病率和卫生系统成本。针对次要衣壳蛋白 L2 的疫苗有可能通过诱导广泛交叉中和血清 IgG,为具有不同属的医学相关 HPV 提供广谱免疫。在这里,我们研究了 L2 特异性血清 IgG 到达生殖道中病毒接种部位以发挥保护作用的机制。阴道上皮的擦伤允许病毒进入并感染基底角质形成细胞,我们的发现表明,这也允许中和 IgG 的局部渗出和疫苗诱导的绝育免疫。我们还证明了 Fc 介导的 L2 抗体-病毒复合物的吞噬作用对于体液免疫很重要,这是当前中和测定未检测到的保护性机制。

相似文献

1
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.Fc 结构域和渗出在 L2 抗体介导的人乳头瘤病毒保护中的作用。
J Virol. 2018 Jul 17;92(15). doi: 10.1128/JVI.00572-18. Print 2018 Aug 1.
2
Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.MHC 类 I 相关的新生儿 Fc 受体(FcRn)在女性生殖道中转移 IgG 赋予阴道感染的保护性免疫。
Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4388-93. doi: 10.1073/pnas.1012861108. Epub 2011 Feb 28.
3
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.基于噬菌体 PP7 VLP 展示 HPV 次要衣壳蛋白 L2 上广泛交叉中和表位的 pan-HPV 疫苗。
PLoS One. 2011;6(8):e23310. doi: 10.1371/journal.pone.0023310. Epub 2011 Aug 17.
4
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.将RG1表位串联体整合到一种自佐剂鞭毛蛋白-L2疫苗中,可扩大对多种人乳头瘤病毒基因型皮肤攻击的持久保护作用。
Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.
5
Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.与靶向人FcγRI的单链抗体片段融合的脂化L2表位重复序列引发了针对多种人乳头瘤病毒类型的交叉中和抗体。
Vaccine. 2016 Nov 4;34(46):5531-5539. doi: 10.1016/j.vaccine.2016.10.009. Epub 2016 Oct 8.
6
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.使用弗林蛋白酶切割的人乳头瘤病毒假病毒对接种基于人乳头瘤病毒L1或L2免疫原的患者的中和血清抗体进行测量。
PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.
7
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
8
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.用具有人乳头瘤病毒16型次要衣壳蛋白L2上交叉中和表位的肽对小鼠进行鼻腔免疫可引发全身和粘膜抗体。
Vaccine. 2001 Jan 8;19(11-12):1496-502. doi: 10.1016/s0264-410x(00)00367-4.
9
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.由展示L2 17 - 36表位的佐剂重组腺相关病毒样颗粒免疫原引发的对致癌性人乳头瘤病毒的持久免疫力。
Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.
10
Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.包装有 L2 基因的乳头瘤病毒假病毒可诱导交叉中和抗体。
J Transl Med. 2010 Mar 24;8:28. doi: 10.1186/1479-5876-8-28.

引用本文的文献

1
Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.系统血清学分析显示,一剂四价人乳头瘤病毒疫苗接种六年之后出现IgG1和IgG3记忆反应。
Nat Commun. 2025 Mar 3;16(1):2130. doi: 10.1038/s41467-025-57443-z.
2
A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration.一种双域工程抗体,可有效抑制乙肝病毒并恢复免疫应答。
Adv Sci (Weinh). 2024 Apr;11(15):e2305316. doi: 10.1002/advs.202305316. Epub 2024 Feb 11.
3
An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.一剂次人乳头瘤病毒疫苗研究、免疫桥接及体液免疫反应的最新进展——会议报告
Prev Med Rep. 2023 Aug 14;35:102368. doi: 10.1016/j.pmedr.2023.102368. eCollection 2023 Oct.
4
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.多功能抗体:为脆弱人群开发精准疫苗的途径。
Front Immunol. 2023 Jun 27;14:1183727. doi: 10.3389/fimmu.2023.1183727. eCollection 2023.
5
Multifaceted roles of Fcγ receptors in COVID-19 and vaccine responses.Fcγ受体在新冠病毒疾病及疫苗反应中的多方面作用
Am J Transl Res. 2023 May 15;15(5):3040-3059. eCollection 2023.
6
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.接种加德西(Gardasil®)和卉妍康(Cervarix®)疫苗后HPV特异性抗体Fc效应器功能的差异。
NPJ Vaccines. 2023 Mar 15;8(1):39. doi: 10.1038/s41541-023-00628-8.
7
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.基于下一代 L2 的 HPV 疫苗可交叉保护免受皮肤乳头瘤病毒感染和肿瘤发展。
Front Immunol. 2022 Oct 3;13:1010790. doi: 10.3389/fimmu.2022.1010790. eCollection 2022.
8
A broadly protective vaccine against cutaneous human papillomaviruses.一种针对皮肤型人乳头瘤病毒的广谱保护性疫苗。
NPJ Vaccines. 2022 Oct 10;7(1):116. doi: 10.1038/s41541-022-00539-0.
9
Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice.人乳头瘤病毒 L2 多聚体疫苗可预防人乳头瘤病毒感染,包括在疣状表皮发育不良模型小鼠中。
Virology. 2022 Oct;575:63-73. doi: 10.1016/j.virol.2022.08.006. Epub 2022 Aug 23.
10
B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination.人乳头瘤病毒(HPV)感染及接种疫苗后的B细胞反应
Vaccines (Basel). 2022 May 25;10(6):837. doi: 10.3390/vaccines10060837.

本文引用的文献

1
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.广泛中和性抗流感抗体在体内发挥保护作用需要Fc受体参与。
J Clin Invest. 2016 Feb;126(2):605-10. doi: 10.1172/JCI84428. Epub 2016 Jan 5.
2
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.人乳头瘤病毒16型(HPV16)L2的血清流行病学及L2特异性人嵌合单克隆抗体的产生
Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.
3
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.使用弗林蛋白酶切割的人乳头瘤病毒假病毒对接种基于人乳头瘤病毒L1或L2免疫原的患者的中和血清抗体进行测量。
PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.
4
Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.抑制剂和L2抗体对多种α和β型人乳头瘤病毒感染性的影响。
PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.
5
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.通过工程化新生儿 Fc 受体(FcRn)结合来延长白蛋白的血清半衰期。
J Biol Chem. 2014 May 9;289(19):13492-502. doi: 10.1074/jbc.M114.549832. Epub 2014 Mar 20.
6
Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model.在免疫功能正常和免疫抑制条件下预防乳头瘤病毒诱导的皮肤肿瘤的保护性疫苗接种:使用天然杂交动物模型的临床前研究。
PLoS Pathog. 2014 Feb 20;10(2):e1003924. doi: 10.1371/journal.ppat.1003924. eCollection 2014 Feb.
7
Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.制备和鉴定一种乳头瘤病毒感染中间体及其在中和研究中的应用。
Virology. 2014 Jan 20;449:304-16. doi: 10.1016/j.virol.2013.10.038. Epub 2013 Dec 20.
8
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.广泛中和血凝素茎特异性抗体需要 FcγR 相互作用才能在体内预防流感病毒。
Nat Med. 2014 Feb;20(2):143-51. doi: 10.1038/nm.3443. Epub 2014 Jan 12.
9
Diseases associated with human papillomavirus infection.与人类乳头瘤病毒感染相关的疾病。
Virology. 2013 Oct;445(1-2):21-34. doi: 10.1016/j.virol.2013.06.007. Epub 2013 Aug 9.
10
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.RG1-VLP 疫苗接种对预防生殖器和皮肤人乳头瘤病毒感染的疗效。
J Invest Dermatol. 2013 Dec;133(12):2706-2713. doi: 10.1038/jid.2013.253. Epub 2013 May 10.